|
Dec 7
|
Shareholders in Arrowhead Pharmaceuticals (NASDAQ:ARWR) have lost 66%, as stock drops 9.3% this past week
|
|
Dec 4
|
Arrowhead seeks approval to begin RNAi therapy trial for obesity treatment
|
|
Dec 3
|
Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity
|
|
Dec 3
|
ARWR: License and Collaboration Deal with Sarepta Includes $825 Million Upon Closing…
|
|
Dec 2
|
Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences
|
|
Sep 24
|
Arrowhead Pharmaceuticals seeks approval for obesity treatment trial in New Zealand
|
|
Sep 23
|
With 73% ownership of the shares, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is heavily dominated by institutional owners
|
|
Sep 23
|
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity
|
|
Jul 24
|
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Third Quarter Results
|
|
Jun 25
|
Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial
|
|
Jun 24
|
Arrowhead Pharmaceuticals Presents Preclinical Data on New RNAi-Based Obesity Program ARO-INHBE
|
|
Jun 3
|
Why Is Arrowhead Pharmaceuticals Stock Trading Higher On Monday?
|
|
Jun 3
|
Arrowhead Pharmaceuticals Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome
|
|
May 31
|
Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences
|
|
May 29
|
Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed Hyperlipidemia
|
|
May 28
|
Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia
|
|
May 20
|
Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma
|
|
May 16
|
ARWR: Summer Webinar Series to Highlight Development Pipeline…
|
|
May 14
|
Double-Up Delights: 7 Stocks Poised to Soar 100% by 2025
|
|
May 10
|
Arrowhead Pharmaceuticals Reports Substantial Fiscal Q2 Loss, Diverging from Analyst Expectations
|